Sol-Gel Technologies Ltd. (SLGL)

NASDAQ: SLGL · IEX Real-Time Price · USD
6.67
0.02 (0.30%)
Jan 28, 2022 1:34 PM EST - Market open
Market Cap154.20M
Revenue (ttm)12.52M
Net Income (ttm)-17.30M
Shares Out23.12M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,866
Open6.64
Previous Close6.65
Day's Range6.25 - 6.67
52-Week Range6.12 - 16.69
Beta1.21
AnalystsBuy
Price Target17.75 (+166.1%)
Earnings Daten/a

About SLGL

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w...

IndustryPharmaceuticals
IPO DateJan 23, 2018
CEOAlon Seri-Levy
Employees65
Stock ExchangeNASDAQ
Ticker SymbolSLGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is 17.75, which is an increase of 166.12% from the latest price.

Price Target
$17.75
(166.12% upside)
Analyst Consensus: Buy

News

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnec...

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...

1 month ago - GlobeNewsWire

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...

1 month ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

NESS ZIONA, Israel, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...

2 months ago - GlobeNewsWire

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...

2 months ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) Earnings Expected to Grow: Should You Buy?

SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 months ago - Zacks Investment Research

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical...

4 months ago - GlobeNewsWire

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical...

4 months ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -75.00% and -71.55%, respectively, for the quarter ended June 2021.

5 months ago - Zacks Investment Research

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

NESS ZIONA, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...

5 months ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SolGel Technologies Ltd. (SLGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

5 months ago - Zacks Investment Research

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric pat...

6 months ago - Benzinga

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...

6 months ago - GlobeNewsWire

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...

6 months ago - GlobeNewsWire

Sol-Gel Announces Pipeline Update and Future Development Plans

NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...

7 months ago - GlobeNewsWire

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in th...

NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world's largest independent dermatology co...

7 months ago - Business Wire

SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 63.27% and -59.15%, respectively, for the quarter ended March 2021.

8 months ago - Zacks Investment Research

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ®

8 months ago - GlobeNewsWire

Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline

SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL

NEW YORK, April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised ...

9 months ago - PRNewsWire

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...

Other symbols:BNGODMTKALDXCYCN
9 months ago - Benzinga

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and ...

9 months ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) Moves 9.7% Higher: Will This Strength Last?

SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume.

9 months ago - Zacks Investment Research

SolGel Technologies Ltd. (SLGL) Stock Jumps 10.8%: Will It Continue to Soar?

SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume.

10 months ago - Zacks Investment Research

SolGel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020.

10 months ago - Zacks Investment Research

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively

10 months ago - GlobeNewsWire